LAVA Therapeutics (LVTX) Price & Analysis

Compare

164 Followers

LVTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.85 - $2.09

Previous CloseN/A

Volume31.56K

Average Volume (3M)122.47K

Market Cap

$39.98M

Enterprise Value-$32.09M

Total Cash (Recent Filing)$66.56M

Total Debt (Recent Filing)$312.00K

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Aug 26, 2025

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding26,305,296

10 Day Avg. Volume257,095

30 Day Avg. Volume122,467

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.80

Enterprise Value/Revenue-6.43

Enterprise Value/Gross Profit-6.74

Enterprise Value/Ebitda1.35

Forecast

1Y Price Target

$1.41

Price Target Upside-7.24% Downside

Rating ConsensusHold

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

AcquisitionXOMA's acquisition of LAVA in a cash-and-CVR deal has been unanimously approved by LAVA’s Board of Directors, potentially bringing benefits to shareholders.

Cash PositionLAVA's cash reserves of approximately $67M are considered sufficient to fund operations into 2027, providing a secure financial runway.

Financial PerformanceLAVA reported better-than-expected financial results with $5M in license revenue and a smaller-than-anticipated net loss, exceeding consensus estimates.

Bears Say

Clinical DataThe sole remaining wholly-owned clinical asset, LAVA-1266, lacks supportive clinical data, raising concerns about its potential success.

Earnings ProjectionThe projection of no revenue and a net loss of $1.46 per share for 2025 may negatively impact investor confidence.

Workforce ReductionThe company announced a workforce reduction of approximately 30%, which may indicate challenges in maintaining operational efficiency.

LAVA Therapeutics News

Lava Therapeutics reports Q2 EPS (32c) vs. (31c) last year

Reports Q2 revenue $0 vs. $0 last year. As of June 30, Lava had cash, cash equivalents, and...

4d ago

LVTX

Lava Therapeutics downgraded to Hold from Buy at Jefferies

Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3,...

12d ago

LVTX

Xoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR

XOMA Royalty (XOMA) and LAVA Therapeutics (LVTX) entered a definitive share purchase agreement whereby XOMA Royalty will acquire...

13d ago

LVTX

XOMA

LAVA Therapeutics Announces Acquisition by XOMA Corporation

LAVA Therapeutics ( ($LVTX) ) has issued an announcement. On August 13, 2025, LAVA Therapeutics announced its acquisition...

3d ago

LVTX

Hold Rating on XOMA’s Acquisition of LAVA Therapeutics: Valuation and Risks Assessed

Analyst Arthur He CFA from H.C. Wainwright reiterated a Hold rating on LAVA Therapeutics and decreased the price...

12d ago

LVTX

LAVA Therapeutics Agrees to Acquisition by XOMA

The latest announcement is out from LAVA Therapeutics ( ($LVTX) ). On August 3, 2025, LAVA Therapeutics entered...

13d ago

LVTX

Lava Therapeutics’ LAVA-1207 Study Terminated: Implications for Investors

Lava Therapeutics Nv (($LVTX)) announced an update on their ongoing clinical study. Study Overview: Lava Therapeutics Nv recently...

16d ago

LVTX

LAVA Therapeutics Shareholders Approve Key Proposals in Meeting

LAVA Therapeutics ( ($LVTX) ) has issued an update. On June 11, 2025, LAVA Therapeutics N.V. held its...

2M ago

LVTX

Hold Rating for LAVA Therapeutics Amid Strategic Changes and Clinical Progress

H.C. Wainwright analyst Arthur He CFA has maintained their neutral stance on LVTX stock, giving a Hold rating...

3M ago

LVTX

Lava Therapeutics reports Q1 EPS (13c) vs (2c) last year

“LAVA’s top priority remains delivering shareholder value through an evaluation of strategic alternatives,” said Steve Hurly, Chief Executive...

3M ago

LVTX

Lava Therapeutics granted full waiver for RVO payment obligation

LAVA Therapeutics (LVTX) announced that the Netherlands Enterprise Agency granted a full waiver of the final payment obligation...

4M ago

LVTX

Hold Rating for LAVA Therapeutics Amid Strategic Review and LAVA-1266 Progress

Arthur He CFA, an analyst from H.C. Wainwright, maintained the Hold rating on LAVA Therapeutics (LVTX – Research...

5M ago

LVTX

Lava Therapeutics Reports 2024 Financial Results

Lava Therapeutics Nv ( ($LVTX) ) has released its Q4 earnings. Here is a breakdown of the information...

5M ago

LVTX

Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year

Reports Q4 revenue $4.99M vs. $353,000 last year. “LAVA’s approach to maximize shareholder value in 2025 will focus...

5M ago

LVTX

LVTX FAQ

What was LAVA Therapeutics’s price range in the past 12 months?

LAVA Therapeutics lowest stock price was $0.85 and its highest was $2.09 in the past 12 months.

What is LAVA Therapeutics’s market cap?

LAVA Therapeutics’s market cap is $39.98M.

When is LAVA Therapeutics’s upcoming earnings report date?

LAVA Therapeutics’s upcoming earnings report date is Aug 26, 2025 which is in 9 days.

How were LAVA Therapeutics’s earnings last quarter?

LAVA Therapeutics released its earnings results on May 14, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.368 by $0.238.

Is LAVA Therapeutics overvalued?

According to Wall Street analysts LAVA Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does LAVA Therapeutics pay dividends?

LAVA Therapeutics does not currently pay dividends.

What is LAVA Therapeutics’s EPS estimate?

LAVA Therapeutics’s EPS estimate is -0.26.

How many shares outstanding does LAVA Therapeutics have?

LAVA Therapeutics has 26,305,296 shares outstanding.

What happened to LAVA Therapeutics’s price movement after its last earnings report?

LAVA Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.368. Following the earnings report the stock price went up 1.6%.

Which hedge fund is a major shareholder of LAVA Therapeutics?

Currently, no hedge funds are holding shares in LVTX

LAVA Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-90.07%

Trailing 12-Months

Asset Growth

-34.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

LAVA Therapeutics

LAVA Therapeutics N.V. (LVTX) is a biotechnology company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary Gammabody™ platform, the company aims to create bispecific antibodies that harness the power of gamma-delta T cells to selectively target and destroy cancerous cells while sparing healthy tissue. LAVA Therapeutics specializes in the research and development of therapies designed to treat various cancer types, offering novel solutions in the oncology sector.

LAVA Therapeutics (LVTX) Earnings & Revenues

Historic Earnings Reports

LVTX Stock 12 Month Forecast

Average Price Target

$1.41

▼(-7.24% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,1.426153846153846,1.4323076923076923,1.4384615384615385,1.4446153846153846,1.4507692307692308,1.456923076923077,1.463076923076923,1.4692307692307691,1.4753846153846153,1.4815384615384615,1.4876923076923076,1.4938461538461538,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,1.419230769230769,1.4184615384615384,1.4176923076923076,1.416923076923077,1.416153846153846,1.4153846153846152,1.4146153846153846,1.4138461538461538,1.413076923076923,1.4123076923076923,1.4115384615384614,1.4107692307692308,{"y":1.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,1.406153846153846,1.3923076923076922,1.3784615384615384,1.3646153846153846,1.3507692307692307,1.3369230769230769,1.323076923076923,1.3092307692307692,1.2953846153846154,1.2815384615384615,1.2676923076923077,1.2538461538461538,{"y":1.24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.67,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >